VIRACTA THERAPEUTICS, INC. Inactive Instrument
Viracta Therapeutics, Inc. Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Presenter SpeechJeff Chen (Analysts)Welcome back to Cowen's 37th Annual Healthcare Conference....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Calendar
2024-06-18
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +64.23% | 62.59B | |
| -2.31% | 41.18B | |
| +43.68% | 40.29B | |
| -8.29% | 27.9B | |
| +11.97% | 26.21B | |
| -21.16% | 19.09B | |
| +7.54% | 13.08B | |
| +27.17% | 12.05B | |
| +25.72% | 12.26B |
